One of the best ways to increase compliance when treating diabetes is to ensure patients fully understand the importance of treatment, according to Yehuda Handelsman, MD, FACP, FACE, FNLA, medical director and principal investigator at the Metabolic Institute of America. However, this can be difficult for physicians with a limited amount of time for patient visits.
One of the best ways to increase compliance when treating diabetes is to ensure patients fully understand the importance of treatment, according to Yehuda Handelsman, MD, FACP, FACE, FNLA, medical director and principal investigator at the Metabolic Institute of America. However, this can be difficult for physicians with a limited amount of time for patient visits.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More